ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KVB K V Pharma CL B

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
K V Pharma CL B NYSE:KVB NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Law Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical Company

21/10/2011 1:47am

Business Wire


K V Pharma CL B (NYSE:KVB)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more K V Pharma CL B Charts.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of purchasers of the common stock of K-V Pharmaceutical Company (“K-V Pharmaceutical” or the “Company”) (NYSE:KV-A) (NYSE:KV-B) between February 14, 2011 and April 4, 2011, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934. The class action lawsuit was filed in the United States District Court for the Eastern District of Missouri.

KV Pharmaceutical is a specialty pharmaceutical company engaged in the acquisition, development, manufacture and marketing of branded and generic/non-branded prescription pharmaceutical products in the United States, primarily focusing on women’s healthcare. The Complaint alleges that during the Class Period defendants issued false and/or misleading statements concerning the Company’s business and financial prospects. Specifically, the Complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted K-V Pharmaceutical the exclusive distribution rights over "Makena," a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing K-V’s competitors from distributing generic formulations of the drug. The Complaint further alleges that defendants failed to disclosed that the drug’s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased K-V Pharmaceutical common stock between February 14, 2011 and April 4, 2011, you have certain rights, and have 60 days from October 19, 2011, to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at 215-638-4847, Toll Free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

1 Year K V Pharma CL B Chart

1 Year K V Pharma CL B Chart

1 Month K V Pharma CL B Chart

1 Month K V Pharma CL B Chart

Your Recent History

Delayed Upgrade Clock